BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1152@pharmaconomics
DTSTAMP:20260707T051032Z
DTSTART;VALUE=DATE:20260331
DTEND;VALUE=DATE:20260401
SUMMARY:ASND Phase 3 — TransCon CNP and TransCon hGH (estimated date)
DESCRIPTION:Phase 3 trial results for TransCon CNP and TransCon hGH in achondroplasia are due ~ Mar 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1612042/000119312526007934/d27768d6k.htm\n\nTrack it: https://www.pharmaconomics.com/e/1152
URL:https://www.pharmaconomics.com/e/1152
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ASND catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR